Loading…

The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome

Purpose: Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder characterized by tissue accumulating CD1a + histiocytes which frequently carry somatic mutations. Irrespective of mutation status, these LCH-cells display constitutively active kinases belonging to the MAPK pathway. We evaluated,...

Full description

Saved in:
Bibliographic Details
Published in:Oncoimmunology 2016-01, Vol.5 (3), p.e1084463-e1084463
Main Authors: Quispel, Willemijn T., Stegehuis-Kamp, Janine A., Blijleven, Laura, Santos, Susy J., Lourda, Magda, van den Bos, Cor, van Halteren, Astrid G.S., Egeler, R. Maarten
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3
cites cdi_FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3
container_end_page e1084463
container_issue 3
container_start_page e1084463
container_title Oncoimmunology
container_volume 5
creator Quispel, Willemijn T.
Stegehuis-Kamp, Janine A.
Blijleven, Laura
Santos, Susy J.
Lourda, Magda
van den Bos, Cor
van Halteren, Astrid G.S.
Egeler, R. Maarten
description Purpose: Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder characterized by tissue accumulating CD1a + histiocytes which frequently carry somatic mutations. Irrespective of mutation status, these LCH-cells display constitutively active kinases belonging to the MAPK pathway. We evaluated, in retrospect, the contribution of individual components of the MAPK-activating and chemotaxis-promoting TNF-CXCR4-CXCL12 axis to LCH manifestation and outcome. Experimental design: CXCR4, CXCL12 and TNF protein expression was immunohistochemically analyzed in 70 LCH-affected biopsies. The presence of CXCR4 + CD1a + cells in peripheral blood (PB) and/or bone marrow (BM) samples was evaluated by flowcytometry in 13 therapy-naive LCH-patients. Results: CXCL12 was detected in 68/70 (97%) biopsies. CXCR4 + LCH-cells were present in 50/70 (71%) biopsies; their presence was associated with higher levels of intralesional TNF. Circulating CD1a + CXCR4 + cells were detected in 4/13 (31%) therapy-naïve LCH-patients which displayed BRAF V600E (2/4), MAP2K1 (1/4) or no (1/4) mutations in their tissues. These CD11c co-expressing CD1a + CXCR4 + cells migrated to CXCL12 in chemotaxis assays. Lesional CXCR4 + LCH-cells were detected in 18/20 cases who presented with LCH manifestation at multiple sites and in 5/23 (22%) patients who developed additional lesions after initially presenting with a single lesion. The CXCR4 status at onset proved to be an independent risk factor for LCH reactivation in multivariate analysis (odds ratio 10.4, p = 0.034). Conclusions: This study provides the first evidence that CXCR4 is involved in the homing and retention of LCH-cells in CXCL12-expressing tissues and qualifies CXCR4 as a candidate prognostic marker for less favorable disease outcome.
doi_str_mv 10.1080/2162402X.2015.1084463
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5323006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1874442195</sourcerecordid><originalsourceid>FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3</originalsourceid><addsrcrecordid>eNp9UltrFDEUHkSxpfYnKHkUytbcN_MiytYbLAhSoW8hmznpRmcna062df-9GfeifdAQyOF8lxOSr2meM3rJqKGvONNcUn5zySlTY0tKLR41p2N_MgKPjzVjJ8054jdal6ZKi_Zpc8INV0pxddr8vF4CWWdAGDyQFMjsZvZFXpDZFXMXxEPfI3GFpAGhjPDcDbeQl27A3yBZRiwx-W1JGJHU7RCTj65AR-5jWRJHekAkwd2l7BZ9nbEpPq3gWfMkuB7hfH-eNV_fv7uefZzMP3_4NHs7n3hpdJmYEKZ-0SovdReA-k5w7cFMmQY9ZSYILToRnOfUi0UIUrRCGOpr6Z1myomzZrLzxXtYbxZ2nePK5a1NLtp963utwMrWaGMqv_0nf51T90d0EDJR72TEVFft6522ElbQeRhKdv1DiwfIEJf2Nt1ZJbio31MNXu4NcvqxASx2FXF8ZzdA2qBlZiql5KxVlap2VJ8TYoZwHMOoHUNiDyGxY0jsPiRV9-LvOx5Vh0hUwpsdIQ4h5ZW7T7nvbHHbPuWQ3eAjWvH_Gb8AogvPLg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1874442195</pqid></control><display><type>article</type><title>The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome</title><source>PubMed Central</source><creator>Quispel, Willemijn T. ; Stegehuis-Kamp, Janine A. ; Blijleven, Laura ; Santos, Susy J. ; Lourda, Magda ; van den Bos, Cor ; van Halteren, Astrid G.S. ; Egeler, R. Maarten</creator><creatorcontrib>Quispel, Willemijn T. ; Stegehuis-Kamp, Janine A. ; Blijleven, Laura ; Santos, Susy J. ; Lourda, Magda ; van den Bos, Cor ; van Halteren, Astrid G.S. ; Egeler, R. Maarten</creatorcontrib><description>Purpose: Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder characterized by tissue accumulating CD1a + histiocytes which frequently carry somatic mutations. Irrespective of mutation status, these LCH-cells display constitutively active kinases belonging to the MAPK pathway. We evaluated, in retrospect, the contribution of individual components of the MAPK-activating and chemotaxis-promoting TNF-CXCR4-CXCL12 axis to LCH manifestation and outcome. Experimental design: CXCR4, CXCL12 and TNF protein expression was immunohistochemically analyzed in 70 LCH-affected biopsies. The presence of CXCR4 + CD1a + cells in peripheral blood (PB) and/or bone marrow (BM) samples was evaluated by flowcytometry in 13 therapy-naive LCH-patients. Results: CXCL12 was detected in 68/70 (97%) biopsies. CXCR4 + LCH-cells were present in 50/70 (71%) biopsies; their presence was associated with higher levels of intralesional TNF. Circulating CD1a + CXCR4 + cells were detected in 4/13 (31%) therapy-naïve LCH-patients which displayed BRAF V600E (2/4), MAP2K1 (1/4) or no (1/4) mutations in their tissues. These CD11c co-expressing CD1a + CXCR4 + cells migrated to CXCL12 in chemotaxis assays. Lesional CXCR4 + LCH-cells were detected in 18/20 cases who presented with LCH manifestation at multiple sites and in 5/23 (22%) patients who developed additional lesions after initially presenting with a single lesion. The CXCR4 status at onset proved to be an independent risk factor for LCH reactivation in multivariate analysis (odds ratio 10.4, p = 0.034). Conclusions: This study provides the first evidence that CXCR4 is involved in the homing and retention of LCH-cells in CXCL12-expressing tissues and qualifies CXCR4 as a candidate prognostic marker for less favorable disease outcome.</description><identifier>ISSN: 2162-4011</identifier><identifier>ISSN: 2162-402X</identifier><identifier>EISSN: 2162-402X</identifier><identifier>DOI: 10.1080/2162402X.2015.1084463</identifier><identifier>PMID: 28255525</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Chemokine receptor CXCR4 ; chemotaxis ; CXCL12 ; Langerhans cell histiocytosis ; Medicin och hälsovetenskap ; Original Research ; prognostic marker</subject><ispartof>Oncoimmunology, 2016-01, Vol.5 (3), p.e1084463-e1084463</ispartof><rights>2016 The Author(s). Published with license by Taylor &amp; Francis Group, LLC © 2016 Willemijn T. Quispel, Janine A. Stegehuis-Kamp, Laura Blijleven, Susy J. Santos, Magda Lourda, Cor van den Bos, Astrid G.S. van Halteren, and R. Maarten Egeler. 2016</rights><rights>2016 The Author(s). Published with license by Taylor &amp; Francis Group, LLC 2016 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3</citedby><cites>FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323006/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5323006/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28255525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:133268376$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Quispel, Willemijn T.</creatorcontrib><creatorcontrib>Stegehuis-Kamp, Janine A.</creatorcontrib><creatorcontrib>Blijleven, Laura</creatorcontrib><creatorcontrib>Santos, Susy J.</creatorcontrib><creatorcontrib>Lourda, Magda</creatorcontrib><creatorcontrib>van den Bos, Cor</creatorcontrib><creatorcontrib>van Halteren, Astrid G.S.</creatorcontrib><creatorcontrib>Egeler, R. Maarten</creatorcontrib><title>The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome</title><title>Oncoimmunology</title><addtitle>Oncoimmunology</addtitle><description>Purpose: Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder characterized by tissue accumulating CD1a + histiocytes which frequently carry somatic mutations. Irrespective of mutation status, these LCH-cells display constitutively active kinases belonging to the MAPK pathway. We evaluated, in retrospect, the contribution of individual components of the MAPK-activating and chemotaxis-promoting TNF-CXCR4-CXCL12 axis to LCH manifestation and outcome. Experimental design: CXCR4, CXCL12 and TNF protein expression was immunohistochemically analyzed in 70 LCH-affected biopsies. The presence of CXCR4 + CD1a + cells in peripheral blood (PB) and/or bone marrow (BM) samples was evaluated by flowcytometry in 13 therapy-naive LCH-patients. Results: CXCL12 was detected in 68/70 (97%) biopsies. CXCR4 + LCH-cells were present in 50/70 (71%) biopsies; their presence was associated with higher levels of intralesional TNF. Circulating CD1a + CXCR4 + cells were detected in 4/13 (31%) therapy-naïve LCH-patients which displayed BRAF V600E (2/4), MAP2K1 (1/4) or no (1/4) mutations in their tissues. These CD11c co-expressing CD1a + CXCR4 + cells migrated to CXCL12 in chemotaxis assays. Lesional CXCR4 + LCH-cells were detected in 18/20 cases who presented with LCH manifestation at multiple sites and in 5/23 (22%) patients who developed additional lesions after initially presenting with a single lesion. The CXCR4 status at onset proved to be an independent risk factor for LCH reactivation in multivariate analysis (odds ratio 10.4, p = 0.034). Conclusions: This study provides the first evidence that CXCR4 is involved in the homing and retention of LCH-cells in CXCL12-expressing tissues and qualifies CXCR4 as a candidate prognostic marker for less favorable disease outcome.</description><subject>Chemokine receptor CXCR4</subject><subject>chemotaxis</subject><subject>CXCL12</subject><subject>Langerhans cell histiocytosis</subject><subject>Medicin och hälsovetenskap</subject><subject>Original Research</subject><subject>prognostic marker</subject><issn>2162-4011</issn><issn>2162-402X</issn><issn>2162-402X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9UltrFDEUHkSxpfYnKHkUytbcN_MiytYbLAhSoW8hmznpRmcna062df-9GfeifdAQyOF8lxOSr2meM3rJqKGvONNcUn5zySlTY0tKLR41p2N_MgKPjzVjJ8054jdal6ZKi_Zpc8INV0pxddr8vF4CWWdAGDyQFMjsZvZFXpDZFXMXxEPfI3GFpAGhjPDcDbeQl27A3yBZRiwx-W1JGJHU7RCTj65AR-5jWRJHekAkwd2l7BZ9nbEpPq3gWfMkuB7hfH-eNV_fv7uefZzMP3_4NHs7n3hpdJmYEKZ-0SovdReA-k5w7cFMmQY9ZSYILToRnOfUi0UIUrRCGOpr6Z1myomzZrLzxXtYbxZ2nePK5a1NLtp963utwMrWaGMqv_0nf51T90d0EDJR72TEVFft6522ElbQeRhKdv1DiwfIEJf2Nt1ZJbio31MNXu4NcvqxASx2FXF8ZzdA2qBlZiql5KxVlap2VJ8TYoZwHMOoHUNiDyGxY0jsPiRV9-LvOx5Vh0hUwpsdIQ4h5ZW7T7nvbHHbPuWQ3eAjWvH_Gb8AogvPLg</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Quispel, Willemijn T.</creator><creator>Stegehuis-Kamp, Janine A.</creator><creator>Blijleven, Laura</creator><creator>Santos, Susy J.</creator><creator>Lourda, Magda</creator><creator>van den Bos, Cor</creator><creator>van Halteren, Astrid G.S.</creator><creator>Egeler, R. Maarten</creator><general>Taylor &amp; Francis</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20160101</creationdate><title>The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome</title><author>Quispel, Willemijn T. ; Stegehuis-Kamp, Janine A. ; Blijleven, Laura ; Santos, Susy J. ; Lourda, Magda ; van den Bos, Cor ; van Halteren, Astrid G.S. ; Egeler, R. Maarten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Chemokine receptor CXCR4</topic><topic>chemotaxis</topic><topic>CXCL12</topic><topic>Langerhans cell histiocytosis</topic><topic>Medicin och hälsovetenskap</topic><topic>Original Research</topic><topic>prognostic marker</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Quispel, Willemijn T.</creatorcontrib><creatorcontrib>Stegehuis-Kamp, Janine A.</creatorcontrib><creatorcontrib>Blijleven, Laura</creatorcontrib><creatorcontrib>Santos, Susy J.</creatorcontrib><creatorcontrib>Lourda, Magda</creatorcontrib><creatorcontrib>van den Bos, Cor</creatorcontrib><creatorcontrib>van Halteren, Astrid G.S.</creatorcontrib><creatorcontrib>Egeler, R. Maarten</creatorcontrib><collection>Taylor &amp; Francis Open Access Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Oncoimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quispel, Willemijn T.</au><au>Stegehuis-Kamp, Janine A.</au><au>Blijleven, Laura</au><au>Santos, Susy J.</au><au>Lourda, Magda</au><au>van den Bos, Cor</au><au>van Halteren, Astrid G.S.</au><au>Egeler, R. Maarten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome</atitle><jtitle>Oncoimmunology</jtitle><addtitle>Oncoimmunology</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>5</volume><issue>3</issue><spage>e1084463</spage><epage>e1084463</epage><pages>e1084463-e1084463</pages><issn>2162-4011</issn><issn>2162-402X</issn><eissn>2162-402X</eissn><abstract>Purpose: Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder characterized by tissue accumulating CD1a + histiocytes which frequently carry somatic mutations. Irrespective of mutation status, these LCH-cells display constitutively active kinases belonging to the MAPK pathway. We evaluated, in retrospect, the contribution of individual components of the MAPK-activating and chemotaxis-promoting TNF-CXCR4-CXCL12 axis to LCH manifestation and outcome. Experimental design: CXCR4, CXCL12 and TNF protein expression was immunohistochemically analyzed in 70 LCH-affected biopsies. The presence of CXCR4 + CD1a + cells in peripheral blood (PB) and/or bone marrow (BM) samples was evaluated by flowcytometry in 13 therapy-naive LCH-patients. Results: CXCL12 was detected in 68/70 (97%) biopsies. CXCR4 + LCH-cells were present in 50/70 (71%) biopsies; their presence was associated with higher levels of intralesional TNF. Circulating CD1a + CXCR4 + cells were detected in 4/13 (31%) therapy-naïve LCH-patients which displayed BRAF V600E (2/4), MAP2K1 (1/4) or no (1/4) mutations in their tissues. These CD11c co-expressing CD1a + CXCR4 + cells migrated to CXCL12 in chemotaxis assays. Lesional CXCR4 + LCH-cells were detected in 18/20 cases who presented with LCH manifestation at multiple sites and in 5/23 (22%) patients who developed additional lesions after initially presenting with a single lesion. The CXCR4 status at onset proved to be an independent risk factor for LCH reactivation in multivariate analysis (odds ratio 10.4, p = 0.034). Conclusions: This study provides the first evidence that CXCR4 is involved in the homing and retention of LCH-cells in CXCL12-expressing tissues and qualifies CXCR4 as a candidate prognostic marker for less favorable disease outcome.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>28255525</pmid><doi>10.1080/2162402X.2015.1084463</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2162-4011
ispartof Oncoimmunology, 2016-01, Vol.5 (3), p.e1084463-e1084463
issn 2162-4011
2162-402X
2162-402X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5323006
source PubMed Central
subjects Chemokine receptor CXCR4
chemotaxis
CXCL12
Langerhans cell histiocytosis
Medicin och hälsovetenskap
Original Research
prognostic marker
title The presence of CXCR4+ CD1a+ cells at onset of Langerhans cell histiocytosis is associated with a less favorable outcome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A21%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20presence%20of%20CXCR4+%20CD1a+%20cells%20at%20onset%20of%20Langerhans%20cell%20histiocytosis%20is%20associated%20with%20a%20less%20favorable%20outcome&rft.jtitle=Oncoimmunology&rft.au=Quispel,%20Willemijn%20T.&rft.date=2016-01-01&rft.volume=5&rft.issue=3&rft.spage=e1084463&rft.epage=e1084463&rft.pages=e1084463-e1084463&rft.issn=2162-4011&rft.eissn=2162-402X&rft_id=info:doi/10.1080/2162402X.2015.1084463&rft_dat=%3Cproquest_pubme%3E1874442195%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c486t-8ff7cb95c46dfe0cd326ce8716e6718f363d3fac20c3bff4393380cbffca615a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1874442195&rft_id=info:pmid/28255525&rfr_iscdi=true